Lee E, Cho J
J Rhinol. 2024; 30(2):69-79.
PMID: 39664874
PMC: 11524355.
DOI: 10.18787/jr.2023.00015.
Castellano C, Sun T, Ravindranathan D, Hwang C, Balanchivadze N, Singh S
Cancer. 2024; 130(12):2191-2204.
PMID: 38376917
PMC: 11141719.
DOI: 10.1002/cncr.35247.
Sim J, Shin J, Lee H, Lee Y, Kim Y
PLoS One. 2024; 19(2):e0296808.
PMID: 38329987
PMC: 10852310.
DOI: 10.1371/journal.pone.0296808.
Amorrortu R, Zhao Y, Keenan R, Gilbert S, Rollison D
J Racial Ethn Health Disparities. 2023; 12(1):107-117.
PMID: 37917235
PMC: 11747054.
DOI: 10.1007/s40615-023-01855-4.
Lanman T, Ruiz A, Nagpal S
Case Rep Oncol. 2023; 16(1):980-987.
PMID: 37900820
PMC: 10601729.
DOI: 10.1159/000531836.
Case-control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study.
Garcia-Donas J, de Velasco G, Madurga R, Chamorro J, Rosero D, Etxaniz O
Clin Transl Oncol. 2023; 26(3):732-738.
PMID: 37556096
DOI: 10.1007/s12094-023-03295-2.
COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.
Moey M, Hennessy C, French B, Warner J, Tucker M, Hausrath D
Transl Oncol. 2023; 34:101709.
PMID: 37302348
PMC: 10235676.
DOI: 10.1016/j.tranon.2023.101709.
Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients.
Leyfman Y, Emmanuel N, Menon G, Joshi M, Wilkerson W, Cappelli J
J Hematol Oncol. 2023; 16(1):39.
PMID: 37055774
PMC: 10100631.
DOI: 10.1186/s13045-023-01432-6.
Impact of COVID-19 in Patients with Lung Cancer: A Descriptive Analysis.
Mojsak D, Debczynski M, Kuklinska B, Minarowski L, Kasiukiewicz A, Moniuszko-Malinowska A
Int J Environ Res Public Health. 2023; 20(2).
PMID: 36674340
PMC: 9866646.
DOI: 10.3390/ijerph20021583.
Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19.
Sagnelli C, Sica A, Creta M, Borsetti A, Ciccozzi M, Sagnelli E
Pathogens. 2022; 11(5).
PMID: 35631088
PMC: 9144674.
DOI: 10.3390/pathogens11050567.
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.
Fu J, Reid S, French B, Hennessy C, Hwang C, Gatson N
JAMA Netw Open. 2022; 5(3):e224304.
PMID: 35344045
PMC: 8961318.
DOI: 10.1001/jamanetworkopen.2022.4304.
Clinical Evidence Generation During a Pandemic: Lessons Learned for Sustaining Progress.
Rivera D, Kluetz P, Abdallah K, Agrawal S, Angus D, Califf R
Cancer J. 2022; 28(2):151-156.
PMID: 35333502
PMC: 9158733.
DOI: 10.1097/PPO.0000000000000589.
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19.
Rubinstein S, Bhutani D, Lynch R, Hsu C, Shyr Y, Advani S
Blood Cancer Discov. 2022; 3(3):181-193.
PMID: 35262738
PMC: 9355598.
DOI: 10.1158/2643-3230.BCD-22-0013.
Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.
Hawley J, Sun T, Chism D, Duma N, Fu J, Gatson N
JAMA Netw Open. 2022; 5(1):e2142046.
PMID: 34982158
PMC: 8728628.
DOI: 10.1001/jamanetworkopen.2021.42046.
COVID-19 vaccination and breakthrough infections in patients with cancer.
Schmidt A, Labaki C, Hsu C, Bakouny Z, Balanchivadze N, Berg S
Ann Oncol. 2021; 33(3):340-346.
PMID: 34958894
PMC: 8704021.
DOI: 10.1016/j.annonc.2021.12.006.
Cancer Australia consensus statement on COVID-19 and cancer care: embedding high value changes in practice.
Milch V, Wang R, Der Vartanian C, Austen M, Hector D, Anderiesz C
Med J Aust. 2021; 215(10):479-484.
PMID: 34689343
PMC: 8662192.
DOI: 10.5694/mja2.51304.
Global cancer research in the era of COVID-19: a bibliometric analysis.
Van Hemelrijck M, Lewison G, Fox L, Vanderpuye V, Murillo R, Booth C
Ecancermedicalscience. 2021; 15:1264.
PMID: 34567249
PMC: 8426029.
DOI: 10.3332/ecancer.2021.1264.
Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic.
Salgia S, Salgia N, Prajapati S, Seghal I, Bautista F, Ruel N
Kidney Cancer. 2021; 5(2):73-78.
PMID: 34368520
PMC: 8341455.
DOI: 10.3233/kca-210115.
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
Gurion R, Rozovski U, Itchaki G, Gafter-Gvili A, Leibovitch C, Raanani P
Haematologica. 2021; 107(3):715-720.
PMID: 34320790
PMC: 8883526.
DOI: 10.3324/haematol.2021.279216.
Impact of the COVID-19 pandemic and related control measures on cancer diagnosis in Catalonia: a time-series analysis of primary care electronic health records covering about five million people.
Coma E, Guiriguet C, Mora N, Marzo-Castillejo M, Benitez M, Mendez-Boo L
BMJ Open. 2021; 11(5):e047567.
PMID: 34006554
PMC: 8130761.
DOI: 10.1136/bmjopen-2020-047567.